Link between Lynch syndrome, hormonal influences, and risk of endometrial cancer
the ONA take:
According to a study published in JAMA, researchers have found an association between the risk of endometrial cancer and the age of first menstrual cycle, having given birth, and hormonal contraceptive use for women with Lynch syndrome.
For the study, researchers analyzed data from 1,128 women with an MMR gene mutation who were included in the Colon Cancer Family Registry. Of those, 133 were diagnosed with endometrial cancer. Results showed that a later age of first menstrual cycle, having given birth, and hormonal contraceptive for 1 year or longer were associated with a reduced risk for developing endometrial cancer. Researchers found no significant association between age at the time of giving first and last birth, age at menopause, and postmenopausal hormonal use and the risk for developing endometrial cancer.
The findings potentially suggest that women with an MMR gene mutation should be counseled on the hormonal influences on the risk of endometrial cancer.
Lynch syndrome is caused by a mutation in one of the MMR genes and between 2% and 5% of endometrial cancer cases are associated with Lynch syndrome.
Researchers have found an association between the risk of endometrial cancer and the age of first menstrual cycle, having given birth, and hormonal contraceptive use for women with Lynch syndrome.
Sign Up for Free e-newsletters
- Managing Chemo Brain in Pediatric Survivors of Childhood Cancer
- Aggressive Therapy Provides No Additional Advantage in Metastatic Prostate Cancer
- Excretion of Volatile Organic Compounds Higher in AYAs Using Vaping Products
- FDA, ASHP Actions to Prevent or Manage Chemotherapy Drug Shortages
- Risk for Cardiovascular Disease Higher in Survivors of Testicular Cancer
- Various Aspects of Palliative Care Focus Associated With Different Outcomes In Cancer
- Cost vs Benefits: The Controversy Over Proton Beam Radiotherapy
- Patient Expectations at Odds With Actual Outcomes for Radiotherapy in Breast Cancer
- Patients Desire More Online Tools and Access
- Metformin Plus Ruxolitinib: A Potential Therapeutic Alternative for Myeloproliferative Neoplasms
- Sexual Quality of Life Decreased During, After Chemotherapy for Digestive Cancers
- CHEMO-SUPPORT: A Nursing Intervention to Relieve Chemotherapy Symptom Burden
- Approach and Management of Checkpoint Inhibitor-related Immune Hepatitis
- Revised AJCC8 Demonstrates Superior Tumor Classification for HNCSCC
- Oral Androgen Receptor Inhibitor Granted FDA Approval for Nonmetastatic CRPC
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|